Got $10,000? I Think DexCom Stock Could Be a Quiet Winner of the GLP?1 Wars
Source: Motley Fool
2026-02-25 09:35:00 ET
Many pharmaceutical companies are looking to develop and market the now highly popular GLP-1 drugs, which help treat diabetes, help patients lose weight, and reduce their risk of a range of conditions linked to obesity. The drugmakers that lead this market over the next decade could reap substantial financial benefits for themselves and their shareholders.
But what if companies outside of the pharmaceutical industry benefit as well? One excellent candidate to do so is DexCom (NASDAQ: DXCM) . Let's consider why this healthcare specialist could be an under-the-radar winner of the GLP-1 boom.
Image source: Getty Images.
DexCom Inc.
NASDAQ: DXCM
DXCM Trading
-1.86% G/L:
$62.745 Last:
1,235,291 Volume:
$63.99 Open:
DXCM Latest News
DXCM Stock Data
$26,708,314,307
386,116,109
0.28%
416
N/A
Medical Equipment & Supplies
Healthcare
US
San Diego
